(UroToday.com) The Interdisciplinary Genitourinary Cancer Forum 2025, held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 2: Local Treatments. Dr. Peter Carroll ...

ASCO 2025, Prostate Cancer, androgen deprivation therapy (ADT), HSV-tk gene, Prodrug, intraprostatic injections of CAN-2409, CAN-2409, CAN-2409 plus Prodrug, External Beam Radiation for Newly ...

Interdisciplinary GU Cancer Forum 2025, prostate cancer, de novo high-volume metastatic hormone-sensitive prostate cancer (mHSPC), Advances in Immunotherapy for prostate cancer, 177Lu-PSMA radioligand ...

(UroToday.com) The Interdisciplinary Genitourinary Cancer Forum 2025, held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 4: Molecular Targeted Imaging and ...

(UroToday.com) The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 3: ...

(UroToday.com) The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 1: ...

Trinity Bivalacqua presented updated results from the BOND-003 cohort C study at EAU 2025, evaluating the efficacy and safety of intravesical cretostimogene grenadenorepvec in high-risk ...

Claudia Kesch's presentation at AUA 2025 introduced the PPP2 nomograms, a refined three-tier risk stratification model for prostate cancer patients based on PSMA PET/CT imaging. The study analyzed ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Jiarou Wang discussing a dose-escalation study of the novel PSMA-targeting drug ...

Alon Weizer presented long-term outcomes of UGN-101 chemoablation for low-grade UTUC at SESAUA 2025. In the OLYMPUS trial, 42 patients achieved a complete response after six weekly UGN-101 ...

ASCO 2024 Kidney Cancer ASCO 2024: What Is Variant Histology Renal Cell Cancer and What Are the Available Treatment Options? ASCO 2024: Phase 1b/2 Study of Combination 177Lu Girentuximab plus ...

(UroToday.com) The 2024 American Urological Association (AUA) annual meeting featured a session on bladder cancer trials in progress, and a presentation by Dr. Roger Li discussing MoonRISe-1, a phase ...